Core Insights - The Chinese pharmaceutical industry is experiencing a surge in Business Development (BD) activities, with significant collaborations and licensing agreements being announced at the beginning of the year [1][3][8] - The total value of licensing agreements for Chinese innovative drugs reached approximately $135.65 billion (about 933.56 billion RMB) in the previous year, with 157 transactions recorded [3] - The trend of BD is expected to continue, driven by the increasing capabilities of domestic innovative drug development and the need for multinational corporations (MNCs) to fill pipeline gaps [5][8] BD Transaction Highlights - Frontier Biotech announced an exclusive licensing agreement with GlaxoSmithKline (GSK) for two small RNA products, with an upfront payment of $40 million (about 27.8 million RMB) and potential milestone payments totaling up to $950 million (about 6.594 billion RMB) [4] - Hengrui Medicine disclosed a partnership with Solstice Oncology, granting exclusive rights for the development and commercialization of HBM4003 outside Greater China, with an upfront payment exceeding $10.5 million (about 7.29 million RMB) and potential milestone payments of up to $1.1 billion (about 7.336 billion RMB) [3][4] Market Trends - The small RNA drug sector is gaining attention, with Frontier Biotech focusing on chronic disease treatments and showcasing potential for first-in-class or best-in-class candidates [6] - The rapid development of small RNA technologies is driving deeper industry collaborations, positioning small RNA drugs as a significant area for BD activities [7] - Domestic BD collaborations are increasingly focused on resource sharing and risk mitigation, contrasting with previous trends that emphasized international partnerships [8][9] Domestic Collaboration Growth - There has been a notable increase in domestic BD transactions, with companies like Zhongsheng Pharmaceutical and Jichuan Pharmaceutical engaging in licensing agreements to enhance their market presence [8][9] - The emphasis on domestic collaborations reflects a trend towards resource integration and technology sharing, aiming to accelerate product development and market entry [9]

Core Insights - The pharmaceutical industry in China is experiencing a surge in business development (BD) activities, particularly in the innovative drug sector, with significant transactions occurring in early 2026 [1][4][10] - Companies like Frontier Biotech and Hengrui Medicine have recently announced exclusive licensing agreements with multinational corporations, indicating a trend of collaboration aimed at global market access [1][4][5] BD Transaction Heat - In 2025, the total value of innovative drug licensing transactions in China reached $135.655 billion, with 157 deals reported [4] - In the first quarter of 2026, the total value of licensing transactions has already reached $33.28 billion, surpassing the highest quarterly figure from 2025 [4] - Hengrui Medicine's agreement with Solstice Oncology includes upfront payments exceeding $105 million and potential milestone payments of up to $1.1 billion [4] - Frontier Biotech's deal with GSK involves an upfront payment of $40 million and potential milestone payments totaling up to $950 million [5] Focus on Small Nucleic Acids - Frontier Biotech's recent licensing agreement highlights the growing interest in small nucleic acid drugs, which are seen as a promising third category of therapeutics alongside small molecules and antibody drugs [7][8] - The company is focusing on chronic disease treatments, with pipelines covering various conditions, indicating a strategic emphasis on innovative drug development [7] - The small nucleic acid sector has seen multiple transactions recently, reflecting its status as a key area for BD activities [7] Domestic Transactions on the Rise - There has been a notable increase in BD collaborations among domestic pharmaceutical companies, moving beyond simple "going global" narratives [9][10] - Recent domestic deals include collaborations between companies like Zhongsheng Pharmaceutical and Qilu Pharmaceutical, as well as partnerships involving Jichuan Pharmaceutical and Kangfang [9] - The focus of domestic BD is on resource sharing and risk mitigation, allowing companies with R&D strengths to partner with those possessing commercialization capabilities [10]

2月23日晚间，科创板创新药企前沿生物（688221.SH）公告，已与葛兰素史克（GSK）达成一项独家授权许可协议，GSK获得公司 两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及商业化权利。 协议显示，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。前沿生物将负责其中一款产品在中 国的I期临床试验推进，并完成另一款产品的IND支持性研究。 小核酸领域再迎重磅BD（商务拓展）交易。 作为交易对价，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并在两个项目中累计获得最高9.5亿美元的基于成 功开发、监管及商业化里程碑的付款，同时享有两款产品全球净销售额的分级特许权使用费。 有业内人士向21世纪经济报道记者指出，当前全球小核酸领域交易持续升温，这笔近10亿美元合作有望改善前沿生物现金流、支撑 研发与平台升级，成为其2020年上市以来持续亏损背景下的重要发展拐点，"不过相较于确定性首付款，后续里程碑兑现情况需持续 跟踪"。 受此利好消息提振，作为春节假期后的首个交易日，前沿生物股价在2月24日早盘高开，截至午间休盘报24.54元/股，上涨8.58%，总 ...

【前沿生物】小核酸A股重磅BD！与GSK达成MASP2单双靶点的BD，获得首付款4kw+近期里程碑1.3kw+里程碑 9.5e美元【东吴医药朱国广团队】 事件：2月23日公告，公司与葛兰素史克GSK达成MASP2单双靶点的两款diRNA全球授权BD，公司将获得首付款 4kw+近期里程碑1.3kw+里程碑9.5e美元。 MASP-2机理：通过特异性抑制MASP-2活性阻断凝集素途径异常激活，减少 【前沿生物】小核酸A股重磅BD！与GSK达成MASP2单双靶点的BD，获得首付款4kw+近期里程碑1.3kw+里程碑 9.5e美元【东吴医药朱国广团队】 FB7013（MASP-2）已经获批IND，适应症为原发性IgA肾病，是全球首个申请临床的MASP-2 siRNA，具备FIC潜 力。 FB7011（MASP-2/CFB，Q6M）靶向凝聚素LP+替代AP双途径，IND准备中。 – 已完成食蟹猴IgA肾病研究，单次给药实现两个靶蛋白最大抑制效率95%+，效果持续13周+。 相较已上市的CFB靶点口服小分子药物伊普可泮，uPCR降幅、uTP降幅、以及eGFR均有提升。 事件：2月23日公告，公司与葛兰素史克GSK达成MA ...

丨2026年2月24日星期二丨 NO.1 和铂医药就新一代CTLA-4抗体达成授权协议及股权合作 2月23日，和铂医药公告称，公司与SOLSTICE ONCOLOGY就HBM4003订立授权协议及股权合作协 议。据此，公司同意向Solstice Oncology授予独家授权，以在大中华区以外地区开发及商业化其临床阶 段组合资产HBM4003。根据该等协议的条款，公司有资格获得价值超过1.05亿美元的前期对价。 2月23日，基石药业公告称，舒格利单抗的新适应证申请已获英国药品和医疗保健用品管理局批准单药 用于治疗肿瘤细胞PD-L1表达≥1%、无表皮生长因子受体敏感突变或ALK、ROS1基因组变异、在含铂 放化疗后未出现疾病进展的、不可切除的III期非小细胞肺癌成人患者。 点评：这是舒格利单抗出海进程的又一里程碑。不过，非小细胞肺癌领域PD-1/PD-L1竞争白热化，基 石药业需依托合作伙伴的本地化商业化能力抢占份额，本次获批更多体现监管认可度与全球化运营能力 的提升。 NO.4 诺和诺德股价大跌，CagriSema临床数据不及预期 2月23日，丹麦药企诺和诺德股价大跌。消息面上，公司公布了CagriSema临床 ...

小核酸药物赛道再添重磅国际合作。 2月23日晚间，前沿生物（688221）公告，公司已于2月16日与跨国药巨头葛兰素史克（GSK）签署独家授权协议，将旗下两款小核酸（siRNA）在研产品 的全球权益授予GSK。 分工明确 权益清晰 根据公告，此次授权的两款产品中，一款候选药物已进入新药临床试验申请（IND）阶段，另一款处于临床前阶段。 根据协议，前沿生物将负责其中一款产品在中国的I期临床试验推进，以及另一款产品的IND支持性研究；GSK则将主导两款产品后续的全球临床开发、 注册申报及商业化工作。 根据协议，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并有望在后续开发、监管和商业化过程中获得最高9.5亿美元的里程碑付 款，交易总金额累计超过10亿美元。此外，前沿生物还将享有两款产品全球净销售额的分级特许权使用费。 前沿生物在公告中表示，此次合作不仅将为公司带来可观的现金流支持，助力核心研发投入与技术平台升级，也标志着其在小核酸药物领域的技术实力获 得国际认可。公司在此次合作中将借助GSK在全球临床开发与商业化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业化、拓 展全球 ...

Company and Industry Summary Company Overview - The company focuses on agricultural protection and pharmaceuticals, covering four main sectors: agricultural protection, pharmaceuticals, functional chemicals, and equipment and engineering technology [1][1] - Established nearly 40 years ago, the company has 8 chemical production bases, 3 mechanical equipment production bases, and 3 R&D centers in China, along with one production base each in the UK and Malaysia [1][1] Key Points Agricultural Protection Sector - The agricultural protection CDMO (Contract Development and Manufacturing Organization) business has emerged from a low point and is now in a stable growth phase, serving major global agricultural protection companies [1][1] - Revenue in this sector is expected to slightly decline in 2023-2024 due to downstream inventory destocking [1][1] Pharmaceutical Sector - The company’s pharmaceutical CDMO business has seen a continuous increase in revenue share over the years, primarily serving the top twenty global pharmaceutical companies [2][2] - The pharmaceutical business is extending into the small nucleic acid drug raw material field, with rapid revenue growth anticipated due to increasing downstream customer demand [3][3] New Energy Sector - The company entered the new energy sector in 2021, with LiFSI (Lithium bis(fluorosulfonyl)imide) already commercialized [3][3] - The completion of technical upgrades for lithium hexafluorophosphate will enable the production of 200,000 tons of electrolyte, with 100,000 tons already constructed, contributing to new revenue streams [3][3] Financial Projections - Projected revenues for 2025-2027 are estimated at 6.312 billion, 7.373 billion, and 8.813 billion yuan, respectively, with net profits of 393 million, 513 million, and 617 million yuan [4][4] - Corresponding price-to-earnings ratios (PE) are expected to be 28.0, 21.5, and 17.8 times, respectively, with an initial coverage rating of "Accumulate" [4][4] Additional Insights - The company is replacing some old production capacity with new capacity for patented products, which is expected to enhance gross margins as the supply of off-patent products clears [2][2] - Strengthening relationships with partners is anticipated to lead to rapid growth in demand for patented products [2][2]

Core Insights - The company has made significant advancements in research and development, particularly with its nucleic acid drug platform, which has received clinical trial acceptance for ABA001, aimed at treating hypertension, expected to enter Phase I trials in Q2 2026 [1] Product Development Progress - STC007, a non-addictive postoperative analgesic, is currently in Phase III clinical trials and is expected to submit a new drug application within 2025, potentially becoming the company's first approved innovative drug [2] - STC008, a targeted cancer drug, has entered a critical clinical stage, with the company accelerating its development through an integrated service network [2] Performance and Operating Conditions - The company has released a revenue forecast for 2025, estimating revenue between 1.192 billion and 1.371 billion yuan, representing a year-on-year growth of 10.57% to 27.15%. The net profit attributable to shareholders is projected to be between 191 million and 229 million yuan, with a year-on-year increase of 7.69% to 29.23%. The formal annual report is expected to be disclosed around April 2026 [3] Strategic Advancement - On January 27, 2026, the company announced the termination of the transaction to acquire 100% equity of Langyan Life through the issuance of shares and convertible bonds, indicating a stronger focus on innovative drug development and a "R&D services + pipeline cultivation" strategy [4] Future Development - The company plans to accelerate the layout of its nucleic acid platform and AI peptide platform for multiple indications in 2026, targeting areas such as fat reduction, muscle gain, high blood sugar, and Alzheimer's disease, with the AI peptide platform expected to add 2-3 new drugs in clinical stages [5]

Core Viewpoint - The report from Guolian Minsheng Securities highlights the synergistic effects of small nucleic acid drugs and GLP-1 class drugs in the weight loss sector, suggesting they could become a "golden duo" for weight management [1][4]. Group 1: Drug Efficacy and Development - Arrowhead has reported promising initial weight loss results from two small nucleic acid drugs targeting INHBE and ALK7, with ARO-INHBE showing an average fat reduction of 9.9% and liver fat reduction of up to 38.6%, alongside a 3.6% increase in lean tissue [1]. - ARO-ALK7 demonstrated a dose-dependent average reduction of ALK7 mRNA by 88%, confirming the TRiM platform's ability to inhibit fat cell gene expression [1]. - Wave Life's WVE-007 targeting liver INHBE showed a 9.4% reduction in visceral fat and a 4.5% overall fat reduction after three months, with a 3.2% increase in lean body mass [3]. Group 2: Market Trends and Collaborations - Major pharmaceutical companies are increasingly investing in small nucleic acid drugs, with Eli Lilly committing $1.2 billion in collaboration with Saint Inbiotech for RNAi candidate drug development for metabolic diseases [3]. - Eli Lilly also invested $1 billion in HAYA's lncRNA platform for obesity and related metabolic disease treatments, while Novo Nordisk partnered with Replicate Bioscience for a $550 million project targeting obesity and type 2 diabetes [3]. - The speed of Chinese pharmaceutical companies in developing small nucleic acid drugs for weight loss is nearly on par with international counterparts, with several companies like Hengrui Medicine and Innovent Biologics actively pursuing this area [5]. Group 3: Investment Recommendations - The report suggests focusing on companies involved in small nucleic acid weight loss targets, including Hengrui Medicine, Chengdu Xian Dao, China National Pharmaceutical Group, East China Pharmaceutical, and others [6].

Investment Rating - The report maintains a "Recommended" rating for companies involved in the small nucleic acid drug sector targeting obesity [4]. Core Insights - The obesity treatment market is gaining significant attention, with GLP-1 drugs demonstrating efficacy in weight loss, but they also have high rebound rates post-treatment and associated muscle loss. Small nucleic acid drugs offer a different approach by targeting fat metabolism at the genetic level [12][21]. - Arrowhead and Wave Life have shown promising initial results for their small nucleic acid drugs ARO-INHBE and WVE-007, respectively, indicating effective fat reduction without muscle loss [22][38]. - The collaboration between major pharmaceutical companies and small nucleic acid drug developers is intensifying, with significant investments aimed at advancing RNAi therapies for metabolic diseases [49]. Summary by Sections 1. Unmet Needs in Obesity Treatment - The report highlights the unmet demand in obesity treatment, emphasizing that small nucleic acid drugs could provide solutions by directly intervening in fat metabolism [12][16]. 2. Initial Efficacy of Small Nucleic Acid Drugs - Arrowhead's ARO-INHBE demonstrated an average fat reduction of 9.9% and a liver fat reduction of 38.6%, while also increasing lean tissue by 3.6% [22][27]. - Wave Life's WVE-007 showed a 9.4% reduction in visceral fat and a 4.5% reduction in total fat after three months, with a 3.2% increase in lean body mass [38][49]. 3. Investment Recommendations - The report suggests focusing on companies developing small nucleic acid drugs for obesity, including HengRui Medicine, Chengdu XianDao, China Biopharmaceutical, and others [50].